Prophylactic effect of recombinant banana lectin in inflammatory bowel diseases: evaluation in a murine model of chemically induced colitis

[R. Miljković]

100 str.

Biohemija - Imunologija / Biochemistry - Immunology

Inflamatorne bolesti creva (IBD), uključujući ulcerozni kolitis i Kronovu bolest, sve su učestalije širom sveta i značajno narušavaju kvalitet života obolelih. Patogeneza ovih bolesti rezultat je složene interakcije genetskih faktora, crevne mikrobiote i uticaja iz spoljašnje sredine. Cilj ove doktorske teze bio je da se ispita efekat rekombinantne izoforme lektina banane (rBanLec), poznatog po svojim imunomodulatornim svojstvima, u eksperimentalnom modelu 2,4,6-trinitrobenzen sulfonskom kiselinom-izazvanog kolitisa u C57BL/6 mišu. rBanLec je primenjivan u dozama od 0,1, 1 i 10 μg/mL (100 μL) pre ili nakon izazivanja eksperimentalnog kolitisa. Težina bolesti procenjivana je na osnovu gubitka telesne težine, skraćenja dužine debelog creva, histopatoloških promena, citokinskog profila i parametara oksidativnog stresa u debelom crevu, kao i lokalnih promena u populaciji imunskih ćelija. Najpovoljniji efekat je postignut primenom 0,1 μg/mL rBanLec, kako jednokratno profilaktički tako i tokom bolesti. Pozitivan efekat primene rBanLec se ogledao u značajnom ublaženju kliničke slike u piku bolesti i ubrzavanju oporavka, a bio je povezan sa smanjenjem intenziteta histoloških promena, povećanjem lokalne koncentracije antiinflamatornih citokina i pojačanom aktivnošću antioksidativnih enzima u debelom crevu. Rezultati ukazuju da primena rBanLec u niskim doza može imati povoljno dejstvo u IBD putem modulacije oksidativnog stresa i imunskog odgovora, što dalje ukazuje na potencijalnu mogućnost primene u kontroli IBD.

The incidence of inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease, continues to increase globally. Given the profound impact of IBDs on patient quality of life, the development of effective preventative and therapeutic strategies remains a critical priority. IBD develops through the combined influence of genetics, gut microbial composition, and environmental triggers. The study utilized a TNBS (2,4,6-trinitrobenzene sulfonic acid)-induced colitis model in C57BL/6 mice to examine the effects of recombinant banan lectin (rBanLec), a mannose-specific lectin known for its immunomodulatory activity. Mice received rBanLec at concentrations of 0.1, 1, and 10 μg/mL (100 μL) prior or after to colitis induction. Disease severity was evaluated through parameters such as body weight loss, colon shortening, histopathological analysis, cytokine profiling, oxidative stress biomarker assessment and local changes in immune cell populations. Treatment with the lowest tested dose of rBanLec (0.1 μg/mL) led to a significant reduction in colitis severity, as evidenced by less weight loss, improved histological outcomes, and a shift toward an antiinflammatory cytokine profile. Furthermore, rBanLec enhanced the activity of key antioxidant enzymes and lowered oxidative stress indicators during peak inflammation. These results suggest that low-dose rBanLec has a protective role in experimental colitis through its ability to attenuate oxidative damage and promote anti-inflammatory immune responses. This positions rBanLec as a promising candidate for future interventions in control of IBD pathology.

IBD, lektin banane (BanLec), imunomodulacija, antiinflamatorna aktivnost, debelo crevo, TNBS izazvani kolitis, citokini, antioksidativni enzimi, C57BL/6 miševi

IBD, banana lectin (BanLec), immunomodulation, anti-inflammatory, colon, TNBSinduced colitis, citokines, antioxidative enzymes, C57BL/6 mice

577.27:616.34-002(043.3)

Tekst